5/16
03:18 am
jagx
Jaguar Health, Inc. (NASDAQ: JAGX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
Jaguar Health, Inc. (NASDAQ: JAGX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
5/14
08:04 am
jagx
Jaguar Health Reports First Quarter 2024 Financial Results [Yahoo! Finance]
Medium
Report
Jaguar Health Reports First Quarter 2024 Financial Results [Yahoo! Finance]
5/14
08:00 am
jagx
Jaguar Health Reports First Quarter 2024 Financial Results
Low
Report
Jaguar Health Reports First Quarter 2024 Financial Results
5/13
12:35 pm
jagx
REMINDER: Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates
Medium
Report
REMINDER: Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates
5/9
10:50 am
jagx
Jaguar Health Announces Submission of Clinical Trial Applications for Crofelemer for the Rare Disease Indications Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome (SBS) in Europe [Yahoo! Finance]
High
Report
Jaguar Health Announces Submission of Clinical Trial Applications for Crofelemer for the Rare Disease Indications Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome (SBS) in Europe [Yahoo! Finance]
5/9
10:35 am
jagx
Jaguar Health Announces Submission of Clinical Trial Applications for Crofelemer for the Rare Disease Indications Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome (SBS) in Europe
High
Report
Jaguar Health Announces Submission of Clinical Trial Applications for Crofelemer for the Rare Disease Indications Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome (SBS) in Europe
5/8
08:40 am
jagx
Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates [Yahoo! Finance]
Medium
Report
Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates [Yahoo! Finance]
5/8
08:30 am
jagx
Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates
Low
Report
Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates
5/8
03:34 am
jagx
Jaguar Health, Inc. (NASDAQ: JAGX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
High
Report
Jaguar Health, Inc. (NASDAQ: JAGX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
5/6
08:30 am
jagx
Crofelemer, Jaguar Health’s Prescription Drug Conditionally Approved by the FDA for Chemotherapy-Induced Diarrhea in Dogs, is the Subject of the Company’s Investigational New Animal Drug Application for the Indication of General Diarrhea in Dogs
Low
Report
Crofelemer, Jaguar Health’s Prescription Drug Conditionally Approved by the FDA for Chemotherapy-Induced Diarrhea in Dogs, is the Subject of the Company’s Investigational New Animal Drug Application for the Indication of General Diarrhea in Dogs
5/3
05:53 am
jagx
Comprehensive MYTESI Market Analysis for Chemotherapy-Induced Diarrhea Revealed in New 2032 Forecast Report [Yahoo! Finance]
Medium
Report
Comprehensive MYTESI Market Analysis for Chemotherapy-Induced Diarrhea Revealed in New 2032 Forecast Report [Yahoo! Finance]
4/30
02:07 am
jagx
Jaguar Health, Inc. (NASDAQ: JAGX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
Jaguar Health, Inc. (NASDAQ: JAGX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
4/29
08:45 am
jagx
Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Pediatric Gastroenterology Conference in Abu Dhabi and Panel Discussion About Microvillus Inclusion Disease (MVID) [Yahoo! Finance]
Low
Report
Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Pediatric Gastroenterology Conference in Abu Dhabi and Panel Discussion About Microvillus Inclusion Disease (MVID) [Yahoo! Finance]
4/29
08:30 am
jagx
Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Pediatric Gastroenterology Conference in Abu Dhabi and Panel Discussion About Microvillus Inclusion Disease (MVID)
High
Report
Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Pediatric Gastroenterology Conference in Abu Dhabi and Panel Discussion About Microvillus Inclusion Disease (MVID)
4/22
08:59 am
jagx
Napo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society (ONS) Congress in Support of Company's Expanding Focus on Cancer Supportive Care [Yahoo! Finance]
Medium
Report
Napo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society (ONS) Congress in Support of Company's Expanding Focus on Cancer Supportive Care [Yahoo! Finance]
4/22
08:45 am
jagx
Napo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society (ONS) Congress in Support of Company’s Expanding Focus on Cancer Supportive Care
High
Report
Napo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society (ONS) Congress in Support of Company’s Expanding Focus on Cancer Supportive Care
4/22
02:07 am
jagx
Jaguar Health, Inc. (NASDAQ: JAGX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
High
Report
Jaguar Health, Inc. (NASDAQ: JAGX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
4/18
09:11 am
jagx
Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care [Yahoo! Finance]
High
Report
Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care [Yahoo! Finance]
4/18
08:30 am
jagx
Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care
High
Report
Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care
4/16
09:15 am
jagx
Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care [Yahoo! Finance]
Medium
Report
Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care [Yahoo! Finance]
4/16
08:30 am
jagx
Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care
High
Report
Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care
4/14
02:08 am
jagx
Jaguar Health, Inc. (NASDAQ: JAGX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
High
Report
Jaguar Health, Inc. (NASDAQ: JAGX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
4/10
11:51 am
jagx
Jaguar Health shareholders approve reverse stock split [Seeking Alpha]
Medium
Report
Jaguar Health shareholders approve reverse stock split [Seeking Alpha]
4/9
04:15 pm
jagx
Jaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholders
High
Report
Jaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholders
4/8
08:49 am
jagx
Jaguar Health Granted Extension Until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirement [Yahoo! Finance]
Medium
Report
Jaguar Health Granted Extension Until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirement [Yahoo! Finance]